<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2504">
  <stage>Registered</stage>
  <submitdate>18/09/2009</submitdate>
  <approvaldate>18/09/2009</approvaldate>
  <nctid>NCT00981981</nctid>
  <trial_identification>
    <studytitle>Effect of the Molecular Weight of Oat ß-glucan on Its Ability to Lower Serum Cholesterol</studytitle>
    <scientifictitle>Effect of Varying Dose and Molecular Weight on the Serum LDL-cholesterol-lowering Properties of Oat ß-glucan</scientifictitle>
    <utrn />
    <trialacronym>Bluebird</trialacronym>
    <secondaryid>GIL8034</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypercholesterolemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Wheat bran
Other interventions - 3g high MW
Other interventions - 4g medium MW
Other interventions - 3g medium MW
Other interventions - 4g low MW

Placebo Comparator: Control - Wheat bran cereal

Active Comparator: 3g high MW - Cereal containing 3g high molecular weight oat beta glucan

Active Comparator: 4g medium MW - Cereal containing 4g oat beta glucan with medium molecular weight

Active Comparator: 3g medium MW - Cereal containing 3g oat beta glucan with medium molecular weight

Active Comparator: 4g low MW - Cereal containing 4g oat beta glucan with low molecular weight


Other interventions: Wheat bran
21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.

Other interventions: 3g high MW
20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight

Other interventions: 4g medium MW
28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight

Other interventions: 3g medium MW
21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight

Other interventions: 4g low MW
28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum LDL-cholesterol lowering effect of 3g high MW beta-glucan</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Correlation between serum LDL-cholesterol lowering and log(MW*C)</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Total cholesterol</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum triglycerides</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum HDL cholesterol</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting serum glucose</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum aspartate transaminase</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum c-reactive protein</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum urea</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum creatinine</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time course of changes in blood lipids</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Macronutrient composition of diet</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptoms questionnaire</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>apolipoprotein B</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum markers of cholesterol absorption and synthesis</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  body mass index 18.5 to 40.0 kg/m^2

          -  no intention to lose or gain weight

          -  fasting total cholesterol 5.0 to 8.0 mmol/L

          -  fasting LDL cholesterol 3.0 to 5.0 mmol/L

          -  consuming diet containing &lt;15% energy from saturated fat</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  use of any cholesterol-lowering drug, herbal or nutritional supplement

          -  regular consumption of oatmeal, oat bran or psyllium - containing cereals

          -  fasting serum triglycerides &gt;4.0mmol/L

          -  serum aspartate transaminase &gt;1.5 times upper limit of normal

          -  serum urea or creatinine &gt;1.8 times upper limit of normal

          -  presence of diabetes or fasting glucose &gt;6.9mmol/L

          -  presence or recent major surgical or medical event

          -  allergy to wheat or oats

          -  presence of condition or drug which alters digestion or absorption of foods</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>367</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>SUGiRS Human Nutrition Unit, School of Molecular &amp; Microbial Biosciences, Unviersity of Sydney - Sydney</hospital>
    <postcode>2006 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Berkshire</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Glycemic Index Laboratories, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>CreaNutrition, AG</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Guelph</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Laval University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Reading Scientific Services Ltd.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Toronto</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Agriculture and Agri-Food Canada</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purposes of this study were:

        1. To determine if a breakfast cereal containing 3g of high molecular weight oat
           beta-glucan fiber would lower low-density lipoprotein (LDL) - cholesterol (the "bad"
           cholesterol) compared to a control cereal containing wheat fiber.

        2. To determine if the LDL-cholesterol-lowering effect of oat beta-glucan fiber was reduced
           when the molecular weight of the fiber was reduced.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00981981</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas MS Wolever, MD, PhD</name>
      <address>Glycemic Index Laboratories, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>